Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoer Xincang Tongqiao Granules
- Development stage
- Unknown
- Lead developer
- Jianmin Group
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Xiaoer Xincang Tongqiao Granules is a traditional Chinese medicine (TCM) Class 1.1 innovative drug developed by Jianmin Group. The formulation is derived from a clinical prescription by Chief Physician Chen Yonghui of the Capital Institute of Pediatrics. It is designed to dispel wind, open the nasal passages, strengthen the spleen, and resolve dampness. The drug is indicated for the treatment of perennial allergic rhinitis (specifically the lung meridian wind-cold syndrome) in pediatric patients aged 2 to 14 years, addressing symptoms such as nasal congestion, nasal itching, sneezing, and loss of appetite. In June 2026, the National Medical Products Administration (NMPA) of China approved its clinical trial application, making it the first dedicated pediatric Chinese patent medicine for allergic rhinitis to enter clinical trials in China.
- Other names
- Xiao'er Xin Cang Tongqiao Granules小儿辛苍通窍颗粒
Beyond the preview
Go deeper on Xiaoer Xincang Tongqiao Granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xiaoer Xincang Tongqiao Granules.